Arbutus Biopharma Corporation
Index- P/E- EPS (ttm)-0.60 Insider Own26.89% Shs Outstand148.75M Perf Week1.20%
Market Cap374.84M Forward P/E- EPS next Y-0.60 Insider Trans0.00% Shs Float109.63M Perf Month-0.39%
Income-76.10M PEG- EPS next Q-0.13 Inst Own29.60% Short Float4.35% Perf Quarter9.52%
Sales33.40M P/S11.22 EPS this Y16.80% Inst Trans-0.12% Short Ratio4.95 Perf Half Y-19.94%
Book/sh1.03 P/B2.46 EPS next Y- ROA-37.00% Target Price6.30 Perf Year-17.59%
Cash/sh1.01 P/C2.50 EPS next 5Y- ROE-66.50% 52W Range1.93 - 6.50 Perf YTD-34.96%
Dividend- P/FCF- EPS past 5Y35.10% ROI- 52W High-61.08% Beta2.25
Dividend %- Quick Ratio5.30 Sales past 5Y49.10% Gross Margin- 52W Low31.09% ATR0.12
Employees85 Current Ratio5.30 Sales Q/Q517.40% Oper. Margin- RSI (14)52.40 Volatility3.36% 4.88%
OptionableYes Debt/Eq0.00 EPS Q/Q59.20% Profit Margin- Rel Volume0.90 Prev Close2.50
ShortableYes LT Debt/Eq0.00 EarningsAug 04 BMO Payout- Avg Volume962.82K Price2.53
Recom2.00 SMA203.65% SMA50-1.76% SMA200-15.49% Volume867,986 Change1.20%
Feb-02-22Upgrade Jefferies Hold → Buy $5
Feb-25-21Initiated Jefferies Hold $5
Dec-17-20Initiated H.C. Wainwright Buy $10
Jul-27-20Resumed JMP Securities Mkt Outperform $10 → $8
Jul-24-20Downgrade Robert W. Baird Outperform → Neutral
May-19-20Upgrade Wedbush Neutral → Outperform
Mar-06-20Upgrade Chardan Capital Markets Neutral → Buy $5
Feb-20-20Initiated Robert W. Baird Outperform $8
Feb-05-20Upgrade JMP Securities Mkt Perform → Mkt Outperform $10
Oct-07-19Reiterated B. Riley FBR Buy $7 → $3
Oct-04-19Downgrade Chardan Capital Markets Buy → Neutral
Oct-16-18Upgrade B. Riley FBR Neutral → Buy $11.50 → $9
Oct-15-18Upgrade Wedbush Underperform → Neutral $5
Oct-12-18Reiterated Chardan Capital Markets Buy $12 → $6.50
Jul-06-18Downgrade B. Riley FBR, Inc. Buy → Neutral $9 → $9
Mar-19-18Resumed Chardan Capital Markets Buy $8.25
Mar-19-18Downgrade Wedbush Outperform → Neutral $9 → $6
Jan-05-18Initiated B. Riley FBR, Inc. Buy $10
Apr-04-17Upgrade Chardan Capital Markets Neutral → Buy $3 → $6
Feb-01-17Reiterated Wedbush Outperform $13 → $10
Aug-10-22 06:26AM  
Aug-04-22 07:30PM  
Jul-21-22 07:30AM  
Jul-20-22 04:10PM  
Jul-06-22 12:00PM  
Jun-28-22 03:36PM  
Jun-25-22 04:05AM  
Jun-08-22 02:05AM  
Jun-06-22 02:45PM  
Jun-02-22 07:30AM  
May-26-22 05:05PM  
May-20-22 03:04PM  
May-17-22 07:30AM  
May-09-22 08:16AM  
May-07-22 08:05AM  
May-05-22 02:30PM  
May-04-22 06:55PM  
May-02-22 07:58AM  
Apr-21-22 07:30AM  
Mar-24-22 02:51PM  
Mar-18-22 01:00PM  
Mar-09-22 08:00AM  
Mar-08-22 04:13AM  
Mar-05-22 06:48AM  
Mar-03-22 05:30PM  
Feb-28-22 11:22AM  
Feb-25-22 10:14AM  
Feb-24-22 05:49PM  
Feb-22-22 05:25PM  
Feb-17-22 07:30AM  
Feb-08-22 05:15PM  
Feb-05-22 08:55AM  
Jan-27-22 09:38AM  
Jan-24-22 07:30AM  
Jan-05-22 08:32AM  
Jan-04-22 07:30AM  
Dec-23-21 12:38PM  
Dec-14-21 07:30AM  
Dec-13-21 10:52AM  
Dec-12-21 06:14AM  
Dec-09-21 01:39PM  
Dec-08-21 07:47AM  
Dec-07-21 07:30AM  
Dec-03-21 11:34AM  
Dec-02-21 01:08PM  
Dec-01-21 06:22PM  
Nov-11-21 07:30AM  
Nov-10-21 04:30PM  
Nov-04-21 11:03PM  
Nov-01-21 04:05PM  
Oct-28-21 03:05PM  
Oct-21-21 07:30AM  
Oct-13-21 06:27AM  
Oct-07-21 11:33AM  
Sep-28-21 07:30AM  
Sep-27-21 08:32AM  
Sep-21-21 07:30AM  
Sep-07-21 08:00AM  
Aug-23-21 08:26AM  
Aug-14-21 03:09AM  
Aug-07-21 10:30AM  
Aug-05-21 08:55AM  
Aug-03-21 08:00AM  
Jul-29-21 08:00AM  
Jul-07-21 07:00AM  
Jul-06-21 10:19AM  
Jun-29-21 07:00AM  
Jun-28-21 06:55AM  
Jun-26-21 07:15AM  
Jun-15-21 01:19AM  
Jun-02-21 07:30AM  
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company's research and development programs include AB-161, an oral HBV RNA destabilizer to destabilize HBV RNA, which leads in the reduction of HBsAg and other viral proteins; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Talon Therapeutics, Inc.; Gritstone Oncology, Inc.; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd.; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate a triple combination of AB-729 for the treatment of chronic HBV infection. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sofia Michael J.Chief Scientific OfficerDec 01Sale5.09200,0001,018,0001,303,403Dec 03 04:02 PM